183 related articles for article (PubMed ID: 19775626)
1. Skin toxicities of targeted therapies.
Segaert S; Chiritescu G; Lemmens L; Dumon K; Van Cutsem E; Tejpar S
Eur J Cancer; 2009 Sep; 45 Suppl 1():295-308. PubMed ID: 19775626
[No Abstract] [Full Text] [Related]
2. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
3. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.
Carles J; Morales R; Perez JM; Suárez C; Rodón J; Valverde C
Eur J Cancer; 2009 Sep; 45 Suppl 1():309-17. PubMed ID: 19775627
[No Abstract] [Full Text] [Related]
4. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome.
Lacouture ME; Lai SE
Br J Dermatol; 2006 Oct; 155(4):852-4. PubMed ID: 16965448
[No Abstract] [Full Text] [Related]
5. Grading of severe follicular rash in patients receiving EGFR inhibitors.
Manganoni AM; Farisoglio C; Ferrari V; Zaniboni A; Beretta G; Meriggi F; Calzavara-Pinton P
Ann Surg Oncol; 2010 Jan; 17(1):349. PubMed ID: 19821000
[No Abstract] [Full Text] [Related]
6. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies in colorectal carcinoma: addressing toxicities associated with EGFR inhibitors.
Biedrzycki BA
ONS Connect; 2007; 22(8 Suppl):33-4. PubMed ID: 17824555
[No Abstract] [Full Text] [Related]
8. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
Arteaga CL; Baselga J
Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709
[No Abstract] [Full Text] [Related]
9. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
[TBL] [Abstract][Full Text] [Related]
10. Clinical approaches to minimize rash associated with EGFR inhibitors.
Oishi K
Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
[TBL] [Abstract][Full Text] [Related]
11. Preemptive management of dermatologic toxicities associated with epidermal growth factor receptor inhibitors.
Boucher J; Olson L; Piperdi B
Clin J Oncol Nurs; 2011 Oct; 15(5):501-8. PubMed ID: 21951736
[TBL] [Abstract][Full Text] [Related]
12. Anti-EGFR therapy update: clinical experience and adverse event insights.
Harari PM
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):3-4. PubMed ID: 16736977
[No Abstract] [Full Text] [Related]
13. Cardiovascular toxicity of molecularly targeted agents.
Strevel EL; Siu LL
Eur J Cancer; 2009 Sep; 45 Suppl 1():318-31. PubMed ID: 19775628
[No Abstract] [Full Text] [Related]
14. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
15. Trichomegaly following treatment with gefitinib (ZD1839).
Pascual JC; Bañuls J; Belinchon I; Blanes M; Massuti B
Br J Dermatol; 2004 Nov; 151(5):1111-2. PubMed ID: 15541102
[No Abstract] [Full Text] [Related]
16. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
Reimer G; Brudler O; Heinrich B; Bangerter M
MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
[No Abstract] [Full Text] [Related]
17. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
Fox LP
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal toxicities of novel agents in cancer therapy.
Asnacios A; Naveau S; Perlemuter G
Eur J Cancer; 2009 Sep; 45 Suppl 1():332-42. PubMed ID: 19775629
[No Abstract] [Full Text] [Related]
19. Skin toxicity caused by EGFR antagonists-an autoinflammatory condition triggered by deregulated IL-1 signaling?
Rodeck U
J Cell Physiol; 2009 Jan; 218(1):32-4. PubMed ID: 18781585
[TBL] [Abstract][Full Text] [Related]
20. New drug therapies and their effect on the skin.
Treudler R
J Dtsch Dermatol Ges; 2009 Jul; 7(7):623-37. PubMed ID: 19614812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
